Browse
Submit Data
Databases
API
Help

Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Actinomycin D-induced mitochondrial stress targets PML during NPM1c-AML therapy

ABSTRACT: Microarrays transcriptomic data analyses from acute myeloid leukemia cell line OCI-AML2 and primary acute myeloid leukemia cells treated with actinomycin D.

ORGANISM(S): Homo sapiens

SUBMITTER: Samuel QUENTIN

PROVIDER: E-MTAB-10397 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

E-MTAB-9209

Project description:Transcriptome of primary acute myeloid leukemia (AML) cells treated with AICAr

2025-01-16 | E-MTAB-9209 | ExpressionAtlas

E-MTAB-3322

Project description:Targeting epigenetic networks mediated by Prmt1 and Kdm4c in acute myeloid leukemia

2019-05-14 | E-MTAB-3322 | ExpressionAtlas

mCG-PML-RARA alters multipotent hematopoiesis.

Project description:Acute promyelocytic leukemia (APL) is associated with PML-RARA expression and late myeloid maturation arrest. The myeloid restriction of PML-RARA dependent leukemia has been recapitulated in multiple mouse models of APL, including PML-RARA expressed from the Ctsg locus (mCG-PR). However, we report here that Ctsg expression is not limited to promyelocytes (as had previously been thought); Ctsg RNA is detectable in KLS cells, and mCG-PR mice express PML-RARA within the same compartment, an event that alters multilineage hematopoiesis. However, these animals only develop myeloid leukemia (consistent with the myeloid restriction of human PML-RARA-associated leukemia). Our results suggest that APL is shaped by myeloid- and development-specific factors that define the ultimate leukemic phenotype rather than PML-RARA acting in a committed myeloid precursor. Bone marrow from individual mice expressing PML-RARA from the murine Ctg locus (mCG-PR) and littermate controls was harvested from both femurs and tibia. Standard cell lysis was performed and total RNA was extracted from the flow sorted KLS and SLAM cells. A total of 13 specimens including 3 x mCG-PR_KLS_6wks, 2 x mCG-PR_KLS_13wks,2 x mCG-PR_SLAM_7wks, 4 x WT_KLS_12-13wks (control) and 2 x WT_SLAM_6wks (control) were analyzed using Affymetrics Mouse Exon 1.0 ST platform.

2010-10-21 | E-GEOD-24728 | biostudies-arrayexpress

Integration of CRISPR-Cas9 Screens and Multi-Omics Profiling Reveals CHD7-ANGPT1 as a Novel Multi-Drug Resistance Axis in AML

Project description:To explore how the loss of function of CHD7 leads to drug resistance in acute myeloid leukemia (AML) cells, we investigated the transcriptional programs regulated by CHD7 in OCI-AML2 cells under different drug treatment conditions. This study aims to uncover the role of CHD7 in drug sensitivity and resistance, providing a theoretical basis for developing new therapeutic strategies.

2025-02-21 | PXD061029 |

RNA-seq expression profiling of OCI-AML2 and OCI-AML3 cells upon CRISPR/Cas9 –mediated disruption of DDX3X RNA binding domain

Project description:Human acute myeloid leukemia cell lines OCI-AML2 and OCI-AML3 were used in a CRISPR/Cas9-mediated approach to specifically target DDX3X’s gene sequences encoding the RNA binding domain of the helicase. DDX3X RNA binding domain is bipartite in the two halves of the helicase core. sgRNAs were designed to target both halves of the domain (named RNA binding domain A and B – RBDA and RBDB). We performed RNA-seq to observe the gene expression changes in both OCI-AML2 and OCI-AML3 cell lines following the not-combined CRISPR/Cas9 –mediated targeting of both regions of the DDX3X RNA binding domain. Control CRISPR/Cas9 performed with no sgRNA expressing vector (named “empty vector”) was performed in both cell lines. The latter condition was used as a control for gene expression changes analysis, for each cell line.

2019-11-23 | E-MTAB-6241 | biostudies-arrayexpress

E-TABM-1208

Project description:Transcription profiling by array of patients with ASXL1 mutations in cytogenetically normal acute myeloid leukemia

2025-01-16 | E-TABM-1208 | ExpressionAtlas

E-GEOD-10746

Project description:Microarray analysis of oral punch biopsies from acute myeloid leukemia (AML) patients treated with chemotherapy

2025-01-16 | E-GEOD-10746 | ExpressionAtlas

mCG-PML-RARA alters multipotent hematopoiesis.

2010-10-21 | GSE24728 | GEO

FLT3-ITD impedes retinoic acid, but not arsenic, responses in murine acute promyelocytic leukemias

Project description:Combined all trans retinoic acid (ATRA) / arsenic regimen cures virtually all acute promyelocytic leukemi (APL) patients. However, APL is often associated with activating FLT3-internal tandem duplication (ITD) mutation and the molecular bases for this effect remain unknown. Using mouse APL models, we demonstrate the FLT3-ITD severely blunts ATRA response.

2019-03-18 | E-MTAB-7566 | biostudies-arrayexpress

Integrated nuclear proteomics and transcriptomics identifies new high frequency dysregulated targets in acute myeloid leukemia

Project description:Acute myeloid leukemia (AML) is characterized by developmental arrest which is thought to arise from transcriptional dysregulation of myeloid development programs. Here, we have analyzed the transcriptome of AML blasts in comparison with normal human CD34+ cells using the HTA 2.0 gene chip. We have compared 18 minimally differentiated AML blasts with cord blood derived normal human CD34+ cells - this study is performed as a parallel analysis to compliment the nuclear proteomic studies.

2019-10-02 | E-MTAB-3873 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data